Advertisement

Growth in Classical Galactosemia

  • M.E. Rubio-Gozalbo
  • B. Panis
  • G.T. Berry
Chapter

Abstract

Many genetic metabolic diseases are often associated with growth abnormalities, usually an impaired growth. Most often postnatal growth is affected. Disease intrinsic factors and diet-related deficiencies are probably the main causes of affected growth. One of the diseases where mild growth abnormalities have been noticed is classic galactosemia. Classic galactosemia is a hereditary disorder of galactose metabolism, caused by deficiency of one of the enzymes of the Leloir pathway, the main pathway responsible for galactose metabolism in the human body. Despite early diagnosis and galactose restriction, complications such as ovarian dysfunction, cognitive impairment, neurological sequelae, and mild growth impairment occur. The pathogenesis of these complications is not completely understood. Main proposed mechanisms are metabolites-induced damage, aberrant glycosylation of complex molecules, and epigenetic changes. Review of the available data on growth in this disease reveals that prenatal growth does not seem impaired whereas during postnatal growth decreased height in childhood and early adolescence in both genders have been reported. Predicted final height is less than target height in many patients, but predicted height can be reached as children can grow beyond the age of 18 years. Risk growth factors in this disease might be hormonal and diet related. Ovarian dysfunction (hypergonadotropic hypogonadism) and suboptimal hormonal replacement therapy in girls and delayed puberty in boys are likely to play a role. Other disease-related factors such as aberrant glycosylation of IGF-1 complex components have been proposed but so far there are no investigations to support this hypothesis. Growth might also be influenced by the soy-based galactose-restricted diet. Also, an intriguing question that needs further study is whether we are simply witnessing the coexistence of constitutional delay in classical galactosemia. Prospective studies in a larger number of patients from different populations are necessary to define the typical phenotype of growth in this disease.

Keywords

Target Height Galactose Metabolism Classical Galactosemia Ovarian Dysfunction Aberrant Glycosylation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

GALE

Galactose-4’ epimerase

GALT

Galactose-1-phosphate uridyltransferase

HC

Head circumference

hGH

Human growth hormone

IGF-1

Insulin-like growth factor-1

IGFBP-3

Insulin-like growth factor binding protein-3

SD

Standard deviation

UDP-Gal

Uridine diphosphate galactose

UDP-Glu

Uridine diphosphate glucose

References

  1. Berry GT, Nissim I, Mazur AT, Elsas LJ, Singh RH, Klein PD, Gibson JB, Lin Z, Segal S. In vivo oxidation of [13C]galactose in patients with galactose-1-phosphate uridyltransferase deficiency. Biochem Mol Med. 1995;56:158–65.PubMedCrossRefGoogle Scholar
  2. Bosch AM, Grootenhuis MD, Bakker HD, Heijmans HS, Wijburg FA, Last BF. Living with classical galactosemia: health-related quality of life consequences. Pediatrics. 2004;113:e423–8.PubMedCrossRefGoogle Scholar
  3. Calderon FR, Phansalkar AR, Crockett DK, Miller M, Mao R. Mutation database for the galactose-1-phosphate uridyltransferase (GALT) gene. Hum Mutat. 2007;28:939–43.PubMedCrossRefGoogle Scholar
  4. Donnell GN, Collado M, Koch R. Growth and development of children with galactosemia. J Pediatr. 1961;58:836–44.PubMedCrossRefGoogle Scholar
  5. Donnell GN, Koch R, Fishler K, Ng WG. Clinical aspects of galactosemia. In: Burman C, Holton JB, Pennock CA, editors. Inherited disorders of carbohydrate metabolism. Lancaster: HTP Press; 1980. pp. 103–15.CrossRefGoogle Scholar
  6. Field TL, Reznikoff WS, Frey PA. Galactose-1-phosphate uridylyltransferase: identification of histidine-164 and histidine-166 as critical residues by site-directed mutagenesis. Biochemistry. 1989;28:2094–9.PubMedCrossRefGoogle Scholar
  7. Firth SM, Baxter RC. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol. 1999;160:379–87.PubMedCrossRefGoogle Scholar
  8. Forges T, Monnier-Barbarino P, Leheup B, Jouvet P. Pathophysiology of impaired ovarian function in galactosaemia. Hum Reprod Update. 2006;12:573–84.PubMedCrossRefGoogle Scholar
  9. Gellerfors P, Axelsson K, Helander A, Johansson S, Kenne L, Lindqvist S, Pavlu B, Skottner A, Fryklund L. Isolation and characterization of a glycosylated form of human insulin-like growth factor I produced in Saccharomyces cerevisiae. J Biol Chem. 1989;264:11444–9.PubMedGoogle Scholar
  10. Holton JB, Walter JH, Tyfield LA. Galactosemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. New York, NY: McGraw-Hill; 2001. pp. 1553–87.Google Scholar
  11. Hsia DY, Walker FA. Variability in the clinical manifestations of galactosemia. J Pediatr. 1961;59:872–83.PubMedCrossRefGoogle Scholar
  12. Janosi JB, Firth SM, Bond JJ, Baxter RC, Delhanty PJ. N-Linked glycosylation and sialylation of the acid-labile subunit. Role in complex formation with insulin-like growth factor (IGF)-binding protein-3 and the IGFs. J Biol Chem. 1999;274:5292–8.PubMedCrossRefGoogle Scholar
  13. Kaufman FR, Koqut MD, Donnell GN, Goebelsmann U, March C, Koch R. Hypergonadotropic hypogonadism in female patients with galactosemia. New Engl J Med. 1981;23:994–8.CrossRefGoogle Scholar
  14. Kaufman FR, Loro ML, Azen C, Wenz E, Gilsanz V. Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia. J Pediatr. 1993;123:365–70.PubMedCrossRefGoogle Scholar
  15. Lai K, Willis AC, Elsas LJ. The biochemical role of glutamine 188 in human galactose-1-phosphate uridyltransferase. J Biol Chem. 1999;5:6559–66.CrossRefGoogle Scholar
  16. Leslie ND, Immerman EB, Flach JE, Florez M, Fridovich-Keil JL, Elsas LJ. The human galactose-1-phosphate uridyltransferase gene. Genomics. 1992;14:474–80.PubMedCrossRefGoogle Scholar
  17. Maskarinec G, Takata Y, Murphy SP, Franke AA, Kaaks R. Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among premenopausal women. Br J Nutr. 2005;94:362–7.PubMedCrossRefGoogle Scholar
  18. Ning C, Reynolds R, Chen J, Yager C, Berry GT, McNamara PD, Leslie N, Segal S. Galactose metabolism by the mouse with galactose-1-phosphate uridyltransferase deficiency. Pediatr Res. 2000;48:211–7.PubMedCrossRefGoogle Scholar
  19. Panis B, Forget PP, van Kroonenburgh MJ, Vermeer C, Menheere PP, Nieman FH, Rubio-Gozalbo ME. Bone metabolism in galactosemia. Bone. 2004;35:982–7.PubMedCrossRefGoogle Scholar
  20. Panis B, Forget PP, Nieman FH, van Kroonenburgh MJ, Rubio-Gozalbo ME. Body composition in children with galactosaemia. J Inherit Metab Dis. 2005;28:931–7.PubMedCrossRefGoogle Scholar
  21. Panis B, Gerver WJM, Rubio-Gozalbo ME. Growth in treated classical galactosemia patients. Eur J Pediatr. 2007;166:443–6.PubMedCrossRefGoogle Scholar
  22. Ridel KR, Leslie ND, Gilbert DL. An updated review of the long-term neurological effects of galactosemia. Pediatr Neurol. 2005;33:153–61.PubMedCrossRefGoogle Scholar
  23. Rubio-Gozalbo ME, Hamming S, van Kroonenburgh MJ, Bakker JA, Vermeer C, Forget PP. Bone mineral density in patients with classic galactosaemia. Arch Dis Child. 2002;87:57–60.PubMedCrossRefGoogle Scholar
  24. Rubio-Gozalbo ME, Panis B, Zimmermann LJ, Spaapen LJ, Menheere PP. The endocrine system in treated patients with classical galactosemia. Mol Genet Metab. 2006;89:316–22.PubMedCrossRefGoogle Scholar
  25. Sardharwalla IB, Wraith JE. Galactosaemia. Nutr Health. 1987;5:175–88.PubMedCrossRefGoogle Scholar
  26. Schweitzer S, Shin Y, Jakobs C, Brodehl J. Long-term outcome in 134 patients with galactosaemia. Eur J Pediatr. 1993;152:36–43.PubMedCrossRefGoogle Scholar
  27. Seppo L, Korpela R, Lönnerdal B, Metsaäniitty L, Juntunen-Backman K, Klemola T, Paganus A, Vanto T. A follow-up study of nutrient intake, nutritional status, and growth in infants with cow milk allergy fed either a soy formula or an extensively hydrolyzed whey formula. Am J Clin Nutr. 2005;82:140–5.PubMedGoogle Scholar
  28. Tyfield L, Reichardt J, Fridovich-Keil J, Croke DT, Elsas LJ 2nd, Strobl W, Kozak L, Coskun T, Novelli G, Okano Y, Zekanowski C, Shin Y, Boleda MD. Classical galactosemia and mutations at the galactose-1-phosphate uridyl transferase (GALT) gene. Hum Mutat. 1999;13:417–30.PubMedCrossRefGoogle Scholar
  29. Vilotte JL. Lowering the milk lactose content in vivo: potential interests, strategies and physiological consequences. Reprod Nutr Dev. 2002;42:127–32.PubMedCrossRefGoogle Scholar
  30. Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990;13:802–18.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Pediatrics and Laboratory Genetic Metabolic DiseasesMaastricht Universital Medical CenterMaastrichtThe Netherlands
  2. 2.Department of PaediatricsMaastricht Universital Medical Center + (MUMC+)MaastrichtThe Netherlands
  3. 3.Division of GeneticsChildren’s Hospital BostonBostonUSA

Personalised recommendations